AP-2 Adaptor Complex-Dependent Enhancement of HIV-1 Replication by Nef in the Absence of the Nef/AP-2 Targets SERINC5 and CD4.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
28 02 2023
Historique:
pubmed: 10 1 2023
medline: 3 3 2023
entrez: 9 1 2023
Statut: ppublish

Résumé

Human immunodeficiency virus type 1 (HIV-1) Nef hijacks the clathrin adaptor complex 2 (AP-2) to downregulate the viral receptor CD4 and the antiviral multipass transmembrane proteins SERINC3 and SERINC5, which inhibit the infectivity of progeny virions when incorporated. In Jurkat Tag T lymphoid cells lacking SERINC3 and SERINC5, Nef is no longer required for full progeny virus infectivity and for efficient viral replication. However, in MOLT-3 T lymphoid cells, HIV-1 replication remains highly dependent on Nef even in the absence of SERINC3 and SERINC5. Using a knockout (KO) approach, we now show that the Nef-mediated enhancement of HIV-1 replication in MOLT-3 cells does not depend on the Nef-interacting kinases LCK and PAK2. Furthermore, Nef substantially enhanced HIV-1 replication even in triple-KO MOLT-3 cells that simultaneously lacked the three Nef/AP-2 targets, SERINC3, SERINC5, and CD4, and were reconstituted with a Nef-resistant CD4 to permit HIV-1 entry. Nevertheless, the ability of Nef mutants to promote HIV-1 replication in the triple-KO cells correlated strictly with the ability to bind AP-2. In addition, knockdown and reconstitution experiments confirmed the involvement of AP-2. These observations raise the possibility that MOLT-3 cells express a novel antiviral factor that is downregulated by Nef in an AP-2-dependent manner.

Identifiants

pubmed: 36622146
doi: 10.1128/mbio.03382-22
pmc: PMC9973267
doi:

Substances chimiques

Antiviral Agents 0
CD4 Antigens 0
Membrane Glycoproteins 0
Membrane Proteins 0
nef Gene Products, Human Immunodeficiency Virus 0
nef protein, Human immunodeficiency virus 1 0
SERINC3 protein, human 0
SERINC5 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0338222

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI127263
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI147869
Pays : United States

Références

J Exp Med. 1994 Jan 1;179(1):115-23
pubmed: 7903679
J Virol. 1996 Oct;70(10):6701-8
pubmed: 8794306
J Virol. 2007 Dec;81(24):13852-64
pubmed: 17928336
Nat Med. 1996 Mar;2(3):338-42
pubmed: 8612235
J Immunol. 2008 Dec 15;181(12):8425-32
pubmed: 19050260
Retrovirology. 2012 Jun 22;9:33
pubmed: 22534017
J Virol. 2007 Apr;81(8):3877-90
pubmed: 17267500
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):7093-7098
pubmed: 29891700
Immunity. 2006 May;24(5):547-61
pubmed: 16713973
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11229-34
pubmed: 9736718
ACS Infect Dis. 2022 Jan 14;8(1):91-105
pubmed: 34985256
Mol Cell Biol. 2000 Apr;20(7):2619-27
pubmed: 10713183
Nature. 2015 Oct 8;526(7572):212-7
pubmed: 26416734
J Virol. 2001 Nov;75(21):10113-7
pubmed: 11581379
J Biol Chem. 1996 Mar 15;271(11):6333-41
pubmed: 8626429
J Virol. 2019 Nov 26;93(24):
pubmed: 31578291
J Cell Biol. 2017 Dec 4;216(12):4141-4151
pubmed: 28978644
Nat Struct Mol Biol. 2020 Sep;27(9):822-828
pubmed: 32719457
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9544-8
pubmed: 2687883
Nat Rev Microbiol. 2014 Aug;12(8):563-74
pubmed: 25029025
J Virol. 2009 Nov;83(22):11528-39
pubmed: 19726522
Sci Signal. 2021 Sep 14;14(700):eabc7611
pubmed: 34520227
Curr Biol. 1999 Jun 17;9(12):613-21
pubmed: 10375525
Curr Biol. 1996 Dec 1;6(12):1677-84
pubmed: 8994833
Science. 1995 Nov 10;270(5238):988-91
pubmed: 7481804
Protein Eng Des Sel. 2012 Dec;25(12):813-20
pubmed: 22942393
J Biol Chem. 2020 Nov 13;295(46):15540-15552
pubmed: 32873704
J Biol Chem. 2020 Oct 30;295(44):15158-15171
pubmed: 32862141
J Virol. 1996 Sep;70(9):6157-61
pubmed: 8709241
EMBO J. 1997 Dec 1;16(23):6964-76
pubmed: 9384576
J Virol. 2015 Dec;89(24):12518-24
pubmed: 26423947
Nature. 1998 Jan 22;391(6665):397-401
pubmed: 9450757
J Virol. 2006 Jan;80(1):130-7
pubmed: 16352537
J Virol. 2018 May 14;92(11):
pubmed: 29514909
Curr Biol. 1999 Dec 2;9(23):1407-10
pubmed: 10607567
Elife. 2014;3:e01754
pubmed: 24473078
Virology. 1999 Nov 10;264(1):5-15
pubmed: 10544125
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5549-53
pubmed: 8516299
Retrovirology. 2011 Aug 05;8:64
pubmed: 21819585
Nature. 1988 Jul 14;334(6178):162-5
pubmed: 3260353
J Virol. 2003 Feb;77(3):2124-33
pubmed: 12525647
J Virol. 2004 Jul;78(13):6864-74
pubmed: 15194762
Retrovirology. 2013 Oct 30;10:125
pubmed: 24172637
AIDS Res Hum Retroviruses. 2013 Apr;29(4):725-31
pubmed: 23151229
Nature. 2015 Oct 8;526(7572):218-23
pubmed: 26416733
Cell Host Microbe. 2015 Oct 14;18(4):409-23
pubmed: 26439863
Small GTPases. 2014;5:
pubmed: 24658305
mBio. 2019 Jun 11;10(3):
pubmed: 31186327
J Virol. 2010 Apr;84(8):3935-48
pubmed: 20147394
J Virol. 2008 Feb;82(3):1249-58
pubmed: 18057255
Nature. 1991 Apr 11;350(6318):508-11
pubmed: 2014052
Cell Host Microbe. 2009 Aug 20;6(2):174-86
pubmed: 19683683
J Virol. 2008 Feb;82(3):1166-74
pubmed: 18032517
Cell. 1994 Mar 11;76(5):853-64
pubmed: 8124721
Curr Biol. 1998 Nov 5;8(22):1235-8
pubmed: 9811606
Virology. 2000 May 25;271(1):9-17
pubmed: 10814565
J Exp Med. 1994 Jan 1;179(1):101-13
pubmed: 8270859
J Virol. 2000 Dec;74(23):11081-7
pubmed: 11070003
Cell Host Microbe. 2019 Jan 9;25(1):73-86.e5
pubmed: 30629922
J Virol. 2021 Jan 27;95(8):
pubmed: 33504599
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13567-72
pubmed: 14597713
Cell. 1991 May 17;65(4):651-62
pubmed: 2032289
Nat Med. 2001 Nov;7(11):1217-24
pubmed: 11689886
J Virol. 2014 Mar;88(5):2633-44
pubmed: 24352444
J Virol. 2002 May;76(9):4625-33
pubmed: 11932428
Curr Biol. 1999 Jun 17;9(12):622-31
pubmed: 10375528
Blood. 2012 Jan 19;119(3):786-97
pubmed: 22123847
Sci Adv. 2021 Oct 29;7(44):eabj7398
pubmed: 34714669
J Cell Biol. 2004 Dec 6;167(5):903-13
pubmed: 15569716
Future Virol. 2013 Apr 1;8(4):
pubmed: 24187576
Biochemistry. 1996 Aug 13;35(32):10256-61
pubmed: 8756680
EMBO J. 1995 Feb 1;14(3):484-91
pubmed: 7859737
J Immunol. 2005 Sep 1;175(5):3157-64
pubmed: 16116206
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1539-43
pubmed: 8108442
mBio. 2015 Sep 08;6(5):e01309-15
pubmed: 26350970
Nat Struct Mol Biol. 2012 Jun 17;19(7):701-6
pubmed: 22705789
Curr Biol. 1996 Nov 1;6(11):1519-27
pubmed: 8939608
J Virol. 1999 Mar;73(3):1964-73
pubmed: 9971776
Immunity. 1997 Mar;6(3):283-91
pubmed: 9075929
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7566-70
pubmed: 1502168
Curr Mol Med. 2007 Mar;7(2):171-84
pubmed: 17346169

Auteurs

Balaji Olety (B)

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Yoshiko Usami (Y)

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Yuanfei Wu (Y)

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Paul Peters (P)

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Heinrich Göttlinger (H)

Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH